oxazolidin-2-one has been researched along with mifepristone in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Garner, CW; Smith, LK; Turnbow, MA | 1 |
| Cornell, S | 1 |
2 other study(ies) available for oxazolidin-2-one and mifepristone
| Article | Year |
|---|---|
The oxazolidinedione CP-92,768-2 partially protects insulin receptor substrate-1 from dexamethasone down-regulation in 3T3-L1 adipocytes.
Topics: 3T3 Cells; Adipocytes; Animals; Benzofurans; Dexamethasone; Down-Regulation; Gene Expression Regulation; Insulin; Insulin Receptor Substrate Proteins; Mice; Mifepristone; Oxazoles; Oxazolidinones; Phosphoenolpyruvate Carboxykinase (GTP); Phosphoproteins; Receptors, Glucocorticoid; RNA, Messenger | 1995 |
A slow start to the new millennium. Zyvox, Concerta and Mifeprex headline the year.
Topics: Abortifacient Agents, Steroidal; Acetamides; Anti-Infective Agents; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Drug Approval; Drug Interactions; Humans; Linezolid; Methylphenidate; Mifepristone; Oxazolidinones; Phytotherapy; United States; United States Food and Drug Administration | 2000 |